中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

原发性肝癌多学科整体治疗方案的设计与实施

王悦华

引用本文:
Citation:

原发性肝癌多学科整体治疗方案的设计与实施

DOI: 10.3969/j.issn.1001-5256.2014.03.004
基金项目: 

北京市卫生系统高层次卫生技术人才培养项目(2009-3-65); 2011年首都医科大学宣武医院院级教学课题; 

详细信息
  • 中图分类号: R735.7

Design and implementation of multidisciplinary holistic treatment regimen for primary liver cancer 

Research funding: 

 

  • 摘要:

    恶性肿瘤的治疗模式正在经历从传统的单项专科治疗向联合治疗,再向多学科综合治疗的转变。笔者提出了以整体医学观为基础的肿瘤多学科整体治疗(MDHT)模式以指导肿瘤综合治疗方案的设计与实施。MDHT模式涉及治疗目标、治疗方法和治疗疗程三个方面。以原发性肝癌为例,可以将整体治疗的靶向目标分为肿瘤局部病灶、区域病灶、系统病灶、器官基础病、全身内环境以及康复等六项基本目标。针对MDHT模式中各项治疗目标,可分别采用多种治疗方法的序贯疗法、同步治疗和交替疗法。整体治疗方案的实施是由不同治疗方法的多个治疗疗程来实现的。在肿瘤MDHT模式中,多学科治疗是治疗方式的体现,整体治疗是治疗目标的追求。MDHT的理念有助于指导多学科团队设计和实施肿瘤综合治疗方案。

     

  • [1]WIGGANS MG, JACKSON SA, FOX BM, et al.The preoperative assessment of hepatic tumours:evaluation of UK regional multidisciplinary team performance[J].HPB Surg, 2013, 2013:861681.
    [2]HIGGINS MC, SOULEN MC.Multimodality approaches for control of hepatocellular carcinoma[J].Tech Vasc Interv Radiol, 2007, 10 (1) :64-66.
    [3]LAMB B, PAYNE H, VINCENT C, et al.The role of oncologists in multidisciplinary cancer teams in the UK:an untapped resource for teamleadership?[J].J Eval Clin Pract, 2011, 17 (6) :1200-1206.
    [4]WU YL.Challenge of malignant neoplasm synthetic therapy[J].J Evid-based Med, 2008, 8 (1) :1-2. (in Chinese) 吴一龙.恶性肿瘤多学科综合治疗的困境[J].循证医学, 2008, 8 (1) :1-2.
    [5]WANG YH.Classification of multidisciplinary synthetic therapy and creation of aggregate treatment mode for hepatocellular carcinoma[J].Chin J Hepatobiliary Surg, 2010, 16 (4) :270-274. (in Chinese) 王悦华.肝癌多学科综合治疗的分级与集合治疗模式的建立[J].中华肝胆外科杂志, 2010, 16 (4) :270-274.
    [6]WANG YH, LIU JF, LI F, et al.Radiofrequency ablation combined with transarterial chemoembolization for unresectable primary liver cancer[J].CMJ, 2009, 122 (8) :889-894.
    [7]CUCCHETTI A, PISCAGLIA F, CESCON M, et al.Systematic review of surgical resection vs radiofrequency ablation for hepatocellular carcinoma[J].World J Gastroenterol, 2013, 19 (26) :4106-4118.
    [8]MAS VR, MALUF DG, DUMUR CI, et al.Molecular techniques for identifying HCC origin and biology after orthotopic liver transplantation[J].Diagn Mol Pathol, 2006, 15 (2) :90-94.
    [9]SHIN JW, CHUNG YH.Molecular targeted therapy for hepatocellular carcinoma:current and future[J].World J Gastroenterol, 2013, 19 (37) :6144-6155.
    [10]LIU MT, LI SH, CHU TC, et al.Three-dimensional conformal radiation therapy for unresectahle hepatocellular carcinoma patients who had failed with or were unsuited for transcatheter arterial chemoemholization[J].Jpn J Clin Oncol, 2004, 34 (9) :532-539.
    [11]SALEM R, LEWANDOWSKI RJ, KULIK L, et al.Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma[J].Gastroenterology, 2011, 140 (2) :497-507.
    [12]YANG W, SHEN ZQ, WANG JY, et al.Current progress in CIK anticancer cytotherapeutic protocol in China[J].Sci Technol Rev, 2008, 26 (6) :73-77. (in Chinese) 杨葳, 沈志奇, 王俊懿, 等.我国新型肿瘤细胞治疗方法CIK的研究与应用现状[J].科技导报, 2008, 26 (6) :73-77.
    [13]THOMAS MB, O'BEIRNE JP, FURUSE J, et al.Systemic therapy for hepatocellular carcinoma:cytotoxic chemotherapy, targeted therapy and immunotherapy[J].Ann Surg Oncol, 2008, 15 (4) :1008-1014.
    [14] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B (2010 version) [J].J Clin Hepatol, 2011, 27 (1) :1-16. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2010年版) [J].临床肝胆病杂志, 2011, 27 (1) :1-16.
    [15]DONG J, JIANG JJ.Explanation of the“Recommendation on antiviral therapy to hepatitis B/C virus related hepatocellular carcinoma”[J].J Clin Hepatol, 2013, 29 (1) :20-24. (in Chinese) 董菁, 江家骥.《HBV/HCV相关性肝细胞癌抗病毒治疗专家建议》解读[J].临床肝胆病杂志, 2013, 29 (1) :20-24.
    [16]KORANGY F, HCHST B, MANNS MP, et al.Immunotherapy of hepatocellular carcinoma[J].Expert Rev Gastroenterol Hepatol, 2010, 4 (3) :345-353.
    [17]LUK JM, WANG X, LIU P, et al.Traditional Chinese herbal medicines for treatment of liver fibrosis and cancer:from laboratory discovery to clinical evaluation[J].Liver Int, 2007, 27 (7) :879-890.
    [18]WANG JS, SUN GZ, YAO NL, et al.Treatment of liver cancer by traditional Chinese medicine[J].Jilin J Tradit Chin Med, 2013, 33 (12) :1209-1211. (in Chinese) 王靖思, 孙桂芝, 姚乃礼, 等.肝癌的中医治疗[J].吉林中医药, 2013, 33 (12) :1209-1211.
    [19]MARTIN RC, EID S, SCOGGINS CR, et al.Health-related quality of life:return to baseline after major and minor liver resection[J].Surgery, 2007, 142 (5) :676-684.
    [20]WANG YH, WANG YJ, ZHENG YM, et al.Clinical thinking training in problem-based learning in multi-disciplinary diagnosis and treatment of hepatocellular carcinoma[J].China Med Education Technol, 2010, 24 (4) :408-411. (in Chinese) 王悦华, 王亚军, 郑亚民, 等.肝细胞癌多学科诊疗临床思维方法的PBL教学体会[J].中国医学教育技术, 2010, 24 (4) :408-411.
    [21]Ministry of Health of the People’s Republic of China.Diagnosis, management and treatment of hepatocellular carcinoma (2011 version) [J].J Clin Hepatol, 2011, 27 (11) :1141-1159. (in Chinese) 中华人民共和国卫生部.原发性肝癌诊疗规范 (2011年版) [J].临床肝胆病杂志, 2011, 27 (11) :1141-1159.
    [22]LAMB B, GREEN JS, VINCENT C, et al.Decision making in surgical oncology[J].Surg Oncol, 2011, 20 (3) :163-168.
    [23]GENNARI L.Therapeutic approach to hepatocellular carcinoma:a difficult choice[J].Ann Ital Chir, 2008, 79 (2) :79-80.
  • 加载中
计量
  • 文章访问数:  2320
  • HTML全文浏览量:  25
  • PDF下载量:  688
  • 被引次数: 0
出版历程
  • 出版日期:  2014-03-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回